Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) FCF Margin (2016 - 2025)

Lineage Cell Therapeutics' FCF Margin history spans 16 years, with the latest figure at 79.86% for Q4 2025.

  • For Q4 2025, FCF Margin rose 16073.0% year-over-year to 79.86%; the TTM value through Dec 2025 reached 133.56%, up 11549.0%, while the annual FY2025 figure was 133.56%, 11549.0% up from the prior year.
  • FCF Margin reached 79.86% in Q4 2025 per LCTX's latest filing, up from 98.56% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 417.38% in Q1 2022 to a low of 1901.53% in Q1 2021.
  • Average FCF Margin over 5 years is 341.18%, with a median of 228.27% recorded in 2024.
  • Peak YoY movement for FCF Margin: tumbled -92177bps in 2021, then skyrocketed 231891bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 12.04% in 2021, then crashed by -3328bps to 412.64% in 2022, then rose by 29bps to 292.62% in 2023, then rose by 18bps to 240.59% in 2024, then surged by 67bps to 79.86% in 2025.
  • Per Business Quant, the three most recent readings for LCTX's FCF Margin are 79.86% (Q4 2025), 98.56% (Q3 2025), and 200.83% (Q2 2025).